Trial Profile
Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Acronyms AURAChinaPK
- Sponsors AstraZeneca
- 12 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Jan 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 18 Jan 2018 Planned End Date changed from 29 Dec 2017 to 31 Dec 2018.